Praxis Precision Medicines, Inc. Common Stock
Compare this stock
PRAX Stock Report Card
$
24%
Performance
Score:
10/100
PRAX returned -57.90% in the last 12 months. Based on SPY's performance of -12.89%, its performance is below average giving it a score of 10 of 100.
Sentiment
Score:
76/100
PRAX had a bullish sentiment score of 75.55% across Twitter and StockTwits over the last 12 months. It had an average of 2.22 posts, 0.11 comments, and 0.44 likes per day.
Technicals
Score:
11/100
PRAX receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
Earnings
Score:
10/100
PRAX has missed earnings 8 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 17 quarters, PRAX has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
Score:
64/100
PRAX has had a higher than average amount of volatility over the last 12 months giving it a score of 63 of 100.
Praxis Precision Medicines, Inc. Common Stock Summary
Nasdaq / PRAX
Healthcare
Biotechnology
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
PRAX scored poorly on our reportcard. Here are some similar companies and how they performed.
